Antipeptide Antibody Responses following Intranasal Immunization: Effectiveness of Mucosal Adjuvants

Toxicity is a major factor limiting the development and use of potent adjuvants for human mucosally delivered vaccines. Novel adjuvant formulations have recently become available, and in the present study two have been used for intranasal immunization with a synthetic peptide immunogen (MAP-M2). Thi...

Disgrifiad llawn

Manylion Llyfryddiaeth

Cyhoeddwyd yn:	Infect Immun
Prif Awduron:	Olszewska, Wieslawa, Partidos, Charalambos D., Steward, Michael W.
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	American Society for Microbiology (ASM) 2000
Pynciau:	Microbial Immunity and Vaccines
Mynediad Ar-lein:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101701/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10948106/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/iai.68.9.4923-4929.2000
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!